ImmunityBio’s (IBRX) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of ImmunityBio (NASDAQ:IBRX) in a research report report published on Monday morning,Benzinga reports. They currently have a $30.00 target price on the stock.

Other equities analysts have also issued reports about the stock. EF Hutton Acquisition Co. I raised shares of ImmunityBio to a “strong-buy” rating in a research report on Wednesday, October 23rd. BTIG Research initiated coverage on ImmunityBio in a report on Friday, January 10th. They issued a “buy” rating and a $6.00 target price for the company.

ImmunityBio Price Performance

Shares of NASDAQ IBRX opened at $3.16 on Monday. The business has a 50-day moving average of $3.39 and a 200-day moving average of $4.02. ImmunityBio has a fifty-two week low of $2.28 and a fifty-two week high of $10.53. The stock has a market capitalization of $2.20 billion, a price-to-earnings ratio of -3.43 and a beta of 0.86.

Hedge Funds Weigh In On ImmunityBio

A number of large investors have recently modified their holdings of the company. Stephens Inc. AR bought a new position in ImmunityBio during the 4th quarter valued at $26,000. China Universal Asset Management Co. Ltd. boosted its holdings in shares of ImmunityBio by 10.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 147,754 shares of the company’s stock worth $378,000 after acquiring an additional 13,788 shares during the period. Mutual Advisors LLC bought a new position in ImmunityBio in the 4th quarter valued at $41,000. Virtu Financial LLC bought a new stake in shares of ImmunityBio during the 3rd quarter valued at about $51,000. Finally, Barclays PLC grew its stake in ImmunityBio by 127.4% in the 3rd quarter. Barclays PLC now owns 361,036 shares of the company’s stock worth $1,344,000 after buying an additional 202,248 shares in the last quarter. 8.58% of the stock is currently owned by institutional investors.

About ImmunityBio

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.